Issue 122 • September 2022

No drugs for prions: new approaches to quell therapeutic scarcity

Can generics producers tackle complex and specialty drugs?

Omicron boosters will reinvigorate injectables manufacturing

In association with

NICE makeover: a new look for the UK's HTAs

UK’s health technology assessments (HTAs) enter a new era following changes at NICE and a growing diversion from EU standards

In association with

Issue 122

Brought to you by

08/22/2022 11:00:33
  • Home | Technology transformation
  • In this issue
  • Contents
  • SHL Medical Company Insight
  • SHL Medical
  • Datwyler Company Insight
  • Datwyler
  • CSafe Global
  • Briefing
  • Industry news
  • The pharma industry briefing
  • Mimotopes Company Insight
  • Mimotopes
  • Comment
  • Tapping into pharma’s growing opportunities in digital health
  • Covid-19 Omicron boosters will reinvigorate injectables manufacturing
  • Implementation of electronic health records will improve the quality of care
  • Despite benefits, long-acting injectables remain underutilised for schizophrenia
  • FDA approves Coherus’ Cimerli for DME, with year-long interchangeability exclusivity
  • UK health data collaboration paves the way to study Long Covid symptoms
  • Molnar-Institute Company Insight
  • Molnar-Institute
  • In Depth
  • A makeover for NICE: a new look for HTAs in the UK
  • No drugs for prions: investigating new approaches to alleviate therapeutic scarc
  • Getting smart with digital pills
  • Do generics producers have what it takes to tackle complex and specialty drugs?
  • Decentralised paediatric clinical trials trending up but study execution critica
  • CMO Moves: Regulatory catalysts for drug manufacturing—August
  • Biolife Solutions
  • In Data
  • Healthtech deals decreased significantly in the pharma industry in H1 2022
  • North America is seeing a hiring boom in pharmaceutical industry machine learnin
  • Artificial intelligence mentions decrease in pharma filings in Q2 of 2022
  • Digital media hiring levels in the pharmaceutical industry rose in June 2022
  • Events
  • Next issue